AbbVie

AbbVie's Imbruvica misses pancreatic cancer endpoints
AbbVie's Imbruvica misses pancreatic cancer endpoints
BioCentury
AbbVie
Imbruvica
clinical trials
PCYC-1137
metastatic pancreatic cancer
Flag link:
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Editas
CRISPR
GSK
Tesaro
Clovis Oncology
M&A
AbbVie
JPMHC 2019
Flag link:
3 Big Reasons Why AbbVie Isn't Worried About Humira
3 Big Reasons Why AbbVie Isn't Worried About Humira
Yahoo/Motley Fool
AbbVie
Humira
JPMHC 2019
Flag link:
AbbVie records $4B impairment on Stemcentrx deal
AbbVie records $4B impairment on Stemcentrx deal
BioCentury
AbbVie
Stemcentrx
M&A
Flag link:
Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly
Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly
Endpoints
AbbVie
Rova-T
Flag link:
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Gilead Sciences
AbbVie
Amgen
Flag link:
AbbVie puts up $105M for Tizona's preclinical I/O drug
AbbVie puts up $105M for Tizona's preclinical I/O drug
BioPharma Dive
AbbVie
Tizona Therapeutics
TTX-030
immuno-oncology
Flag link:
AbbVie Strikes Deal With Lupin for Blood Cancer Program
AbbVie Strikes Deal With Lupin for Blood Cancer Program
BioSpace
AbbVie
Lupin
India
MALT1 inhibitors
Flag link:
The Most Promising Biotech Names Heading Into 2019
The Most Promising Biotech Names Heading Into 2019
Investopedia
biotech
AbbVie
Novavax
Amarin
TG Therapeutics
Flag link:
The biotechs promising to slow down aging
The biotechs promising to slow down aging
GoinPharma
Unity Biotechnology
Life Length
AbbVie
Calico
aging
Flag link:
AbbVie gets rights to Lupin's MALT1 program
AbbVie gets rights to Lupin's MALT1 program
BioCentury
AbbVie
Lupin
MALT1 inhibitors
Flag link:
AbbVie streamlines management team to 4 executives under CEO Gonzalez
AbbVie streamlines management team to 4 executives under CEO Gonzalez
Fierce Pharma
AbbVie
reorganization
Richard Gonzalez
Pharma CEOs
Flag link:
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Reuters
Eli Lilly
psoriatic arthritis
Taltz
AbbVie
Humira
clinical trials
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
ASH successes set to lift Imbruvica in CLL
ASH successes set to lift Imbruvica in CLL
Biopharma Dive
AbbVie
Imbruvica
CLL
JNJ
ASH 2018
Flag link:
AbbVie suffers fresh setback with lung cancer drug Rova-T
AbbVie suffers fresh setback with lung cancer drug Rova-T
Pharmaforum
AbbVie
Rova-T
lung cancer
advanced SCLC
Flag link:
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
Fierce Pharma
AbbVie
biosimilars
Pfizer
Humira
patents
Flag link:
AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena
AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena
Fierce Pharma
AbbVie
Venclexta
Roche
AML
Flag link:
Rheostat Therapeutics Raises $23 Million from Heavyweight Pharma Companies in Series A Round
Rheostat Therapeutics Raises $23 Million from Heavyweight Pharma Companies in Series A Round
CP Wire
Rheostat Therapeutics
Merck
AbbVie
Amgen
Flag link:
Why Abbvie Is Down 5% in 2018 So Far
Why Abbvie Is Down 5% in 2018 So Far
Motley Fool
AbbVie
Imbruvica
Humira
Orilissa
Flag link:

Pages